Clinical equipoise and risk-benefit assessment

Clinical Trials

Volumn 9, Issue 5, 2012, Pages 621-627

  Miller, Franklin G ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL RESEARCH; EQUIPOISE; HEALTH CARE QUALITY; HUMAN; MAJOR DEPRESSION; MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; STUDY DESIGN; TREATMENT OUTCOME;

HUMANS; NONTHERAPEUTIC HUMAN EXPERIMENTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; THERAPEUTIC EQUIPOISE;

EID: 84867507870     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774512450952     Document Type: Article

References (23)

1. The Common Rule. Code of Federal Regulations Title. 1991 ; 45 ( 2 ):
2. Freedman B. Equipoise and the ethics of clinical research. New Engl J Med. 1987 ; 317: 141-45
3. Weijer C. The ethical analysis of risk. J Law Med Ethics. 2000 ; 28: 344-61
4. Weijer C, Miller PB. When are research risks reasonable in relation to anticipated benefits?. Nat Med. 2004 ; 10: 570-73
5. Weijer C, Miller PB. Refuting the net risks test: A response to Wendler and Miller's 'Assessing research risks systematically'. J Med Ethics. 2007 ; 33: 487-90
6. Ethical and Policy Issues in Research Involving Human Participants. Washington, DC: National Bioethics Advisory Commission ; 2000: 69-95.
7. Miller FG, Brody H. A critique of clinical equipoise: Therapeutic misconception in the ethics of clinical trials. Hastings Cent Rep. 2003 ; 33 (3). 19-28
8. Miller FG, Joffe S. Equipoise and the randomized clinical trial dilemma. New Engl J Med. 2011 ; 364: 476-80
9. Wendler D, Miller FG. Assessing research risks systematically: The net risks test. J Med Ethics. 2007 ; 33: 481-86
10. Freedman B, Glass KC, Weijer C. Placebo orthodoxy in clinical research. II: Ethical, legal, and regulatory myths. J Law Med Ethics. 1996 ; 24: 252-59
11. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the food and drug administration database. Arch Gen Psychiat. 2000 ; 57: 311-17
12. DeFelice A, Willard J, Lawrence J, et al. The risks associated with short-term placebo-controlled antihypertensive clinical trials: A descriptive meta-analysis. J Human Hypertens. 2008 ; 22: 659-68
13. The Common Rule. Code of Federal Regulations Title. 1991 ; 45 :
14. Hirschfeld RMA, Keck PE, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: A 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004 ; 161: 1057-65
15. Temple R, Ellenberg SE. Placebo-controlled trials and active-control trials in the evaluation of new treatments: Part 1: Ethical and scientific issues. Ann Intern Med. 2000 ; 133: 455-63
16. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials-A middle ground. New Engl J Med. 2001 ; 345: 915-19
17. Rid A, Wendler D. A framework for risk-benefit evaluations in biomedical research. Kennedy Inst Ethic J. 2011 ; 21: 141-79
18. Jansen LA. A closer look at the bad deal trial: Beyond clinical equipoise. Hastings Cent Rep. 2005 ; 35 (5). 29-36
19. Bullock TL, Andriole GL. Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Dr. 2006 ; 11: 111-23
20. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasis: Pooled results of 2 phase 3 studies. J Urology. 2009 ; 181: 2634-40
21. Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011 ; 59: 342-52
22. van der Graaf R, van Delden JJ. Equipoise should be amended, not abandoned. Clin Trials. 2011 ; 8: 408-16
23. Gifford F. Pulling the plug on clinical equipoise: A critique of Miller and Weijer. Kennedy Inst Ethic J. 2007 ; 17: 203-26